TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06166862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation and motor imagery therapy for rehabilitation
Description: Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham action observation and motor imagery therapy for rehabilitation
Description: Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions.
Study: NCT04779593

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical examination
Description: Clinical data will be recorded (general clinical examination, height, weight, blood pressure,heart beat, alcohol and tobacco consumption, antecedent) as well as concurrent medication at each follow-up visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: Clinical data will be recorded (general clinical examination, height, weight, blood pressure,heart beat, alcohol and tobacco consumption, antecedent) as well as concurrent medication at each follow-up visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SF36 questionnaire
Description: At D0, M12 and M24. This 36 item patient reported survey of patient's health is the most commonly used and validated health survey instrument for appraising quality of life.~Items are grouped in 8 scaled scores exploring multiple dimension of global health (vitality, physical functioning, bodily pain, general health, perceptions, physical role functioning, emotional role functioning, social role functioning, mental health).~Scoring will be performed as recommended by the SF-36 instruction manual to create the eight scale scores. Furthermore, these subscales sum to obtain the total SF-36 score and will be summarized into two composite scores (physical and mental quality of life).
Study: NCT04856475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: As per investigator's choice, eligible subjects in all cohort will receive:~* Neratinib, administered continuously at a dose of 240 mg orally once a day in combination with:~  * Capecitabine, administered continuously at a dose of 750 mg/m2, orally, twice a day (=daily dose of 1500 mg/m2) from D1 toD14 (21 days cycle) (preferred option) or~ * Vinorelbine, I.V. 25 mg/m2 on D1 and D8 (21 days cycle) or~ * Paclitaxel, I.V. 80 mg/m2 on D1, D8, and D15 (21 days cycle) Important note: The possibility to combine trastuzumab, loading dose 8 mg/kg IV followed by 6 mg/kg Q3W IV or SC 600 mg Q3W, to one of these above treatments is left at investigator's discretion OR~* Neratinib, administered continuously at a dose of 160 mg, orally, once a day in combination with:~  * T-DM1, I.V. 3.6mg/m2 on D1 (21 days cycle) (preferred option)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: As per investigator's choice, eligible subjects in all cohort will receive:~* Neratinib, administered continuously at a dose of 240 mg orally once a day in combination with:~  * Capecitabine, administered continuously at a dose of 750 mg/m2, orally, twice a day (=daily dose of 1500 mg/m2) from D1 toD14 (21 days cycle) (preferred option) or~ * Vinorelbine, I.V. 25 mg/m2 on D1 and D8 (21 days cycle) or~ * Paclitaxel, I.V. 80 mg/m2 on D1, D8, and D15 (21 days cycle) Important note: The possibility to combine trastuzumab, loading dose 8 mg/kg IV followed by 6 mg/kg Q3W IV or SC 600 mg Q3W, to one of these above treatments is left at investigator's discretion OR~* Neratinib, administered continuously at a dose of 160 mg, orally, once a day in combination with:~  * T-DM1, I.V. 3.6mg/m2 on D1 (21 days cycle) (preferred option)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: As per investigator's choice, eligible subjects in all cohort will receive:~* Neratinib, administered continuously at a dose of 240 mg orally once a day in combination with:~  * Capecitabine, administered continuously at a dose of 750 mg/m2, orally, twice a day (=daily dose of 1500 mg/m2) from D1 toD14 (21 days cycle) (preferred option) or~ * Vinorelbine, I.V. 25 mg/m2 on D1 and D8 (21 days cycle) or~ * Paclitaxel, I.V. 80 mg/m2 on D1, D8, and D15 (21 days cycle) Important note: The possibility to combine trastuzumab, loading dose 8 mg/kg IV followed by 6 mg/kg Q3W IV or SC 600 mg Q3W, to one of these above treatments is left at investigator's discretion OR~* Neratinib, administered continuously at a dose of 160 mg, orally, once a day in combination with:~  * T-DM1, I.V. 3.6mg/m2 on D1 (21 days cycle) (preferred option)
Study: NCT05702255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active acupressure
Description: Participants will receive training (2 sessions, 2 days a part) by a training researcher. Patients will be taught on the acupoints location and the acupressure technique. Participants will be verified for the correct location of the acupoints, acupressure technique and strength. Participants will be instructed to use thumb or middle finger to self- press each acupoint using circular movements. The force of pressing must be sufficiently strong but still within a comfortable range. A lubricant will be uses to decrease friction between the acupoints and the finger. Follow up evaluation will be at the end of the week 2 and week 4 .The training researcher will make weekly calls to remind participants to perform acupressure and to answer questions

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acuptressure
Description: The same protocol as the active acupressure group.
Study: NCT06248294

Intervention type: DIAGNOSTIC_TEST
Intervention: CT follow-up
Description: Computed tomography angiography assessment of BAV-related aorthopathy
Study: NCT04779593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF36 questionnaire
Description: At D0, M12 and M24. This 36 item patient reported survey of patient's health is the most commonly used and validated health survey instrument for appraising quality of life.~Items are grouped in 8 scaled scores exploring multiple dimension of global health (vitality, physical functioning, bodily pain, general health, perceptions, physical role functioning, emotional role functioning, social role functioning, mental health).~Scoring will be performed as recommended by the SF-36 instruction manual to create the eight scale scores. Furthermore, these subscales sum to obtain the total SF-36 score and will be summarized into two composite scores (physical and mental quality of life).
Study: NCT06559761

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: According to guideline recommended procedure of hepatectomy

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: According to guideline recommended procedure of hepatectomy

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: According to guideline recommended procedure of hepatectomy

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: According to guideline recommended procedure of hepatectomy
Study: NCT05426395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 2.6 µg
Description: There are four groups of women (n = 20 total) who will receive B12 dosing once daily, including group 1a (sufficient baseline B12, pregnant), group 1b (sufficient baseline B12, non-pregnant), group 1c (insufficient baseline B12, pregnant), and group 1d (insufficient baseline B12, non-pregnant).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 10 µg
Description: There are two groups of women (n = 10 total) who will receive B12 dosing once daily, including group 2a (sufficient baseline B12, pregnant) and group 2b (insufficient baseline B12, pregnant).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 50 µg
Description: The participants (n = 20 total) will be randomly assigned to receive either a once per day B12 dose or a twice per day B12 dose. The four groups at this dose level include: group 3a (sufficient baseline B12, pregnant, Q12), group 3b (sufficient baseline B12, Q24), group 3c (insufficient baseline B12, pregnant, Q12), group 3d (insufficient baseline B12, Q24).
Study: NCT06339424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon radiotherapy
Description: * 39.6-72.6 Gy in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 30-66 Gy in 10 fractions for tumors \>1 cm from the hepatic hilum, bowel, and heart.~* 27.5-50 Gy in 5 fractions using stereotactic body radiation therapy (SBRT) techniques
Study: NCT04779593

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AIMS2_SF questionnaire
Description: At D0, M12 and M24. The Arthritis Impact Measurement Scales 2 Short Form (AIMS2-SF) is a specific tool to measure changes in global health, pain, mobility and social function in patients with arthritis. It was described in 1992 in patients with rheumatoid arthritis and osteoarthritis and include 26 items that are summarized in scales according to a predefined scoring system: mobility, physical activity (walking, bending, lifting), dexterity, household activity (managing money and medications, housekeeping), social activities, activities of daily living, pain, depression, and anxiety. The French translation has been validated and this questionnaires has been widely used in the rheumatology field to assess quality of life of patients with arthritis. Because HFE related arthropathy is very similar to osteoarthritis this questionnaire is ought to be adequate in this setting.
Study: NCT06405243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myoinositol
Description: Myoinositol decreases insulin resistance and consequently increased intracellular glucose uptake, restore the metabolic profile and induce ovulation in PCOS patients with infertility, in addition to its good safety profile

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chromium
Description: chromium picolinate may potentiates the therapeutic effect of letrozol on pituitary hormones (FSH and LH), improvement of ovulation, normalization of Estrogen level, improvement of endometrial thickness related to ovulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-arginine
Description: new antioxidant that minimizes the inflammatory reaction, the hormonal imbalance, and the metabolic disturbances in PCO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: selective aromatase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: selective aromatase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: selective aromatase inhibitor
Study: NCT04566497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No stress testing
Description: No stress testing during the patient follow up (up to 48 months) if the patient remains asymptomatic

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stress testing
Description: Systematic annual stress testing during the patient follow up (up to 48 months)
Study: NCT05716503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Description: Patients Will Receive negative pressure wound therapy dressings before skin grafting to prepare the wound bed and after skin grafting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ordinary dressings with antibiotic ointment and gauze
Description: Patients will Receive once daily dressing with antibiotic ointment and gauze before and after skin grafting.
Study: NCT06780436

Intervention type: DEVICE
Intervention: 3D Transcranial Ultrasound Brain Imaging
Description: The system implements a proprietary transcranial imaging methodology, which measures the profile of the skull bone and the speed of sound in it to accurately focus the ultrasound energy from a phased array probe through the bone in order to detect hematoma boundaries with resolution normally obtainable only through the open skull.

Intervention type: DEVICE
Intervention: 3D Transcranial Ultrasound Brain Imaging
Description: The system implements a proprietary transcranial imaging methodology, which measures the profile of the skull bone and the speed of sound in it to accurately focus the ultrasound energy from a phased array probe through the bone in order to detect hematoma boundaries with resolution normally obtainable only through the open skull.
Study: NCT05518591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Focused Therapy (CFT) combined with Breathing Pattern Retraining (BPR)
Description: Study participants in the experimental arm of the study are being asked to take part in a 6-week, virtual, psychological therapy group involving compassion focused therapy and breathing pattern retraining. This group involves exercises in practicing self-compassion, emotional regulation, and breathing retraining. Each group session lasts less than two hours, per week.
Study: NCT06346808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oncolytic virus Plus Anti-PD1 and Chemotherapy
Description: Oncolytic virus，Camrelizumab ，AG（Gemcitabine +Capecitabine ）
Study: NCT06035055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Description: 9g ceftolozane/tazobactam in 240 millilitres 0.9% sodium chloride IV infusion given over 24 hours for 10-14 days
Study: NCT04230720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Complete
Description: 1 drop 4 times a day for 14 days
Study: NCT04697381

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: somatropin - GH naïve pediatric cohort
Description: somatropin 0.245 mg/kg/week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: somatropin - GH treated cohort
Description: somatropin 0.084 mg/kg/week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: somatropin - adult cohort
Description: somatropin 0.084 mg/kg/week
Study: NCT06134453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki/Sham Reiki
Description: Reiki will be applied to the patients by the research nurse who is at the Reiki master level. Sham Reiki will remain in the same position and for the same duration as if Reiki was performed by a healthcare professional who has not received Reiki training, but Reiki energy will not be given to the patient. No intervention will be made to the control group.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Reiki/Sham Reiki
Description: Reiki will be applied to the patients by the research nurse who is at the Reiki master level. Sham Reiki will remain in the same position and for the same duration as if Reiki was performed by a healthcare professional who has not received Reiki training, but Reiki energy will not be given to the patient. No intervention will be made to the control group.
Study: NCT06780306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTAX03
Description: Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord
Study: NCT05753904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conjoint Tendon Resection
Description: For conjoint tendon resection in the experimental group, the conjoint tendon will be released completely via a transverse incision made at a level 2 cm distal to the coracoid process for the patients assigned the conjoint resection group. Electrocautery will be used for the resection, and the underlying muscular portion of the conjoint tendon will be preserved.
Study: NCT06024980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open partial horizontal laryngectomy(OPHL), Type I-III
Description: An open partial horizontal laryngectomy(OPHL) was performed for patients with T2 supraglottic and glottic carcinoma, according to the American Joint Committee on Cancer(AJCC) criteria. Type I OPHL: Entails the resection of the supraglottis, including the pre-epiglottic space and the upper half of the thyroid cartilage. Type II OPHL: Entails the resection of the entire thyroid cartilage, with the inferior limit represented by the upper edge of the cricoid ring. Type III OPHL: Entails the resection of the entire supraglottic, glottic, and part of the subglottic sites, sparing both or at least one functioning crico-arytenoid unit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transoral endoscopic laser cordectomy
Description: For patients with T1 glottic laryngeal carcinoma, according to the criteria of the American Joint Committee on Cancer(AJCC), transoral endoscopic CO2 laser(2-40Watts) cordectomy was performed. The classification comprises eight types of cordectomies:~* A subepithelial cordectomy (type I) is a resection of the epithelium of the vocal fold.~* A subligamental cordectomy (type II) is a resection of the epithelium, Reinke's space, and vocal ligament.~* Transmuscular cordectomy (type III), which proceeds through the vocalis muscle.~* Total cordectomy (type IV).~* Extended cordectomy encompasses the contralateral vocal fold and the anterior commissure (type Va).~* Extended cordectomy, which includes the arytenoid (type Vb).~* Extended cordectomy, which encompasses the subglottis (type Vc).~* Extended cordectomy, which consists of the ventricle (type Vd).
Study: NCT04652622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindful Garden
Description: Mindful Garden is an interactive digital behavior modification platform utilizing inbuilt sensors and screen based delivery system. The platform delivers calming visual output of real nature video layered with hyper-real animations of growing and receding flowers and butterflies in flight in a volume directly responsive to measured patient activity. Patient movement and vocalization are the surrogate markers for agitation and using proprietary algorithms drive onscreen content.
Study: NCT04955158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 75 µg dexmedetomidine soaked pharyngeal pack (Group D) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 50 mg ketamine soaked pharyngeal pack (Group K) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline 0.9%
Description: 20 ml 0.9% saline soaked pharyngeal pack (Group C) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
Study: NCT04935580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC012F injection
Description: GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.
Study: NCT06205264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training at high and low speeds.
Description: The training program will last for 8 weeks with a frequency of 3 sessions per week. Session duration will be 40-60 minutes, depending on the week within the developed schedule. To form the groups, participants will be randomly divided into two groups. On one hand, the explosive group will perform exercises in less time with faster movements, while the conventional group will execute the training with slower movements. The entire session will be designed and supervised by three exercise specialists. Each child must have a written informed consent completed by their parent/guardian.~Three days of strength training will be conducted following WHO recommendations, emphasizing multi-joint exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training at high and low speeds.
Description: The training program will last for 8 weeks with a frequency of 3 sessions per week. Session duration will be 40-60 minutes, depending on the week within the developed schedule. To form the groups, participants will be randomly divided into two groups. On one hand, the explosive group will perform exercises in less time with faster movements, while the conventional group will execute the training with slower movements. The entire session will be designed and supervised by three exercise specialists. Each child must have a written informed consent completed by their parent/guardian.~Three days of strength training will be conducted following WHO recommendations, emphasizing multi-joint exercises.
Study: NCT06780306

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TTAX03
Description: Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TTAX03
Description: Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: 300 mL Sterile, preservative free 0.9% NaCl
Study: NCT05485974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-2438
Description: KRAS G12C Inhibitor